The Latest Breaking News from Pfizer

The COVID-19 vaccine is getting an upgrade.

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic. Pfizer shares fell nearly 1%, while BioNTech US-listed shares were down about 1.5%…

The Biden administration plans to begin offering next-generation COVID-19 booster shots as soon as the Labor Day weekend, according to people familiar with the matter, aiming to stave off a fall surge in cases of the disease.

The company said it believes its rivals’ vaccine infringes on patents Moderna filed between 2010 and 2016

Pharmaceuticals Pfizer and BioNTech say they have asked the European Medicines Agency to authorize their updated coronavirus booster vaccine that includes the most recent omicron subvariants

The vaccine maker alleges that its rivals Pfizer and BioNTech used some patented features of its mRNA technology to develop their COVID vaccines.

The vaccine maker said it had filed patent infringement lawsuits in the US and Germany.

Moderna seeks unspecified damages in lawsuit over rivals’ jab

High levels of coronavirus antibodies among the population means the rate of serious illness remains low

Social media users shared a range of false claims this week